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Abstract
Background: Genomic instability plays an important role in human cancers. We previously characterized genomic
instability in esophageal squamous cell carcinomas (ESCC) in terms of loss of heterozygosity (LOH) and copy
number (CN) changes in tumors. In the current study we focus on biallelic loss and its relation to expression of
mRNA and miRNA in ESCC using results from 500K SNP, mRNA, and miRNA arrays in 30 cases from a high-risk
region of China.
Results: (i) Biallelic loss was uncommon but when it occurred it exhibited a consistent pattern: only 77 genes (<0.5 %)
showed biallelic loss in at least 10 % of ESCC samples, but nearly all of these genes were concentrated on just four
chromosomal arms (ie, 42 genes on 3p, 14 genes on 9p, 10 genes on 5q, and seven genes on 4p). (ii) Biallelic loss was
associated with lower mRNA expression: 52 of the 77 genes also had RNA expression data, and 41 (79 %) showed
lower expression levels in cases with biallelic loss compared to those without. (iii) The relation of biallelic loss to miRNA
expression was less clear but appeared to favor higher miRNA levels: of 60 miRNA-target gene pairs, 34 pairs (57 %)
had higher miRNA expression with biallelic loss than without, while 26 pairs (43 %) had lower miRNA expression. (iv)
Finally, the effect of biallelic loss on the relation between miRNA and mRNA expression was complex. Biallelic loss was
most commonly associated with a pattern of elevated miRNA and reduced mRNA (43 %), but a pattern of both
reduced miRNA and mRNA was also common (35 %).
Conclusion: Our results indicate that biallelic loss in ESCC is uncommon, but when it occurs it is localized to a few
specific chromosome regions and is associated with reduced mRNA expression of affected genes. The effect of biallelic
loss on miRNA expression and on the relation between miRNA and mRNA expressions was complex.
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Background
Esophageal cancer is the eighth most common and the
sixth most frequent fatal human cancer in the world [1]
and the fourth most common incident cancer in China
[2]. Shanxi Province, a region in north central China, has
among the highest esophageal cancer rates in China and
nearly all of these cases are esophageal squamous cell
carcinoma (ESCC). ESCC is an aggressive tumor which is
typically diagnosed only after the onset of symptoms when
prognosis is very poor. The 19 % 5-year survival rate is
fourth worst among all cancers in the USA [3]. One
promising strategy to reduce ESCC mortality is early
detection. Further, a better understanding of the molecu-
lar mechanisms underlying esophageal carcinogenesis and
its molecular pathology will facilitate the development of
biomarkers for early detection.
Genomic instability is one of several mechanisms that
can lead to gene dysregulation and has been thought to
play an important role in the etiology of human cancers,
including both histologic types of esophageal cancer,
esophageal adenocarcinoma and ESCC [4, 5]. In previous
studies using a variety of different methods we found that
LOH was common in ESCCs from Shanxi Province in
north central China. These studies identified over 20
common LOH regions, frequent copy number alterations
(both gain and loss), as well as numerous copy number
neutral regions, which suggests that this cancer is charac-
terized by genomic instability [5, 6]. In addition, somatic
mutations in several genes with critical roles in carcino-
genesis (e.g., TP53, CDKN2A, and BRCA2) have been
identified in ESCC patients with LOH in regions that in-
clude the genes [7–9], indicating that a wide variety of
DNA alterations in numerous genes occur in the develop-
ment of this tumor.
Gene expression microarray technology is an important
tool for evaluating tumor heterogeneity and has been suc-
cessfully applied to identify subsets of tumors (including
within ESCC) with different clinical parameters such as
survival, histological grade, invasive status, and response to
therapy [10–15]. In recent years, miRNAs have emerged as
a major class of regulatory genes, and one class of miR-
NAs, conserved miRNA, has targets which can now be
predicted with confidence. It is thought that the role of
miRNAs is to control expression of target genes. Thus,
dysregulation of miRNA is expected in human diseases
such as cancer, which are attributed to dysregulation of
gene expression in tumor suppressors and oncogenes
[16–18]. Further, dysregulation of some miRNAs has been
related to patient survival in some cancers, including
ESCC [19, 20]. Biallelic loss is thought to play a critical
role in tumor pathogenesis, especially because of its influ-
ence on expression of affected genes (mRNA) and related
miRNA, however, these relations have not been well stud-
ied in ESCC. Since cancer is a complex disease, it is
increasingly important that analyses combine the evalu-
ation of alterations in DNA and RNA, including those that
occur in both mRNA and miRNA, in order to better
understand their potential interactions in the development
of cancers.
It has become clear that human genetic variation
ranges from single nucleotide changes at the sequence
level up to multi-megabase chromosomal aberrations.
Of the molecular genetic changes that occur during the
development of human cancer, alterations in SNPs are
likely among the earliest or even the initial events that
lead to genomic instability. While studying large changes
(eg, big deletions, inversions, and translocations at the
chromosomal level) in tumor cells is informative,
knowledge of the more numerous small alterations that
occur at the nucleotide sequence level are equally or more
critical to our understanding of the detailed process of
carcinogenesis, particularly at its earliest stages. For
example, biallelic loss in genes may cause double strand
breaks which result in widespread structural rearrange-
ments of the genome. However, how alterations of DNA
(i.e., biallelic loss) influence gene expression remains
largely unknown, especial for SNPs that are not in coding
regions.
In the present study, we performed global profiling of
alterations in DNA as well as expression of mRNA and
miRNA in tumors and their matched normal tissues
from 30 ESCC cases. Using these profiles, we identified
genes with biallelic loss and examined their mRNA
expression and miRNA targets as an initial step in un-
derstanding relations among these small alterations in
nucleic acids in ESCC.
Methods
Case selection
This study was approved by the Institutional Review
Boards of the Shanxi Cancer Hospital and the US National
Cancer Institute (NCI). Briefly, cases diagnosed with
ESCC between 1998 and 2001 in the Shanxi Cancer
Hospital in Taiyuan, Shanxi Province, PR China, and con-
sidered candidates for curative surgical resection were
identified and recruited to participate in this study after
obtaining written informed consent. None of the cases
had prior therapy and Shanxi was the ancestral home for
all. Cases ranged in age from 39 to 67 years (median 56
years) and were predominantly female (63 %). Clinically,
most cases had Stage 2 (77 %) cancers and half had
evidence of metastasis at diagnosis. The ESCC cases
studied here were previously evaluated for LOH and copy
number alterations using genome-wide arrays [5, 6].
Biological specimen collection and processing
Venous blood (10 ml) was taken from each case prior to
surgery and germline DNA from whole blood was
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extracted and purified using the standard phenol/chloro-
form method. Tumor and adjacent normal tissues were
dissected at the time of surgery and stored in liquid nitro-
gen until used. DNA was extracted from micro-dissected
tumor as previously described [5] using the protocol from
the Puregene DNA Purification Tissue Kit (Gentra Sys-
tems, Inc., Minneapolis, MN).
RNA was extracted from 17 of the micro-dissected tu-
mors and their matched normal tissue pairs as described
previously using the protocol from the PureLink Micro-
to-Midi Total RNA Purification System (Catalog num-
ber 12183–018, Invitrogen, Carlsbad, CA) [5]; total
RNA from 13 cases was isolated by using the Allprep
kit (Qiagen) per the manufacturer’s instructions. RNA
quality and quantity were determined using the RNA
6000 Labchip/Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Germantown, MD).
Target preparation for GeneChip human mapping 500K
array set
The Affymetrix GeneChip Human Mapping 500K array
set was previously performed in these patients (6, 7). The
set array contains ~262,000 (Nsp I array) and ~238,000
(Sty I array) SNPs (mean probe spacing = 5.8Kb, mean
heterozygosity = 27 %). A detailed gene chip protocol
can be found at http://www.affymetrix.com/support/
downloads/manuals/500k_assay_manual.pdf.
Experiments were conducted according to the proto-
col (GeneChip Mapping Assay manual) supplied by
Affymetrix, Inc. (Santa Clara, CA). Genotype calls were
generated by GTYPE v 4.0 software (Affymetrix). Paired
germ-line and tumor DNA from each case were run to-
gether in parallel in the same experiment (ie, same
batch, same day). The GEO accession number for these
SNP array data is GSE15526.
Probe preparation and hybridization for Human Genome
U133A 2.0 array
The Affymetrix Human Genome U133A 2.0 array is a
single array used to interrogate expression of 14,500
well-characterized human genes. Array experiments
were performed using 1-5ug total RNA for each array as
described previously [10]. We followed the protocol pro-
vided by the manufacturer to carry out reverse transcription,
labeling, and hybridization. (http://www.affymetrix.com/sup-
port/technical/manual/expression_manual.affx). RNA from
paired tumor and normal esophageal tissues were run
together in parallel in the same experiment. The GEO
accession number for these expression array data is
GSE38129.
ABI miRNA expression array by RT-PCR
The TaqMan® Low Density Array was used to determine
microRNA expression in this study, which employed the
9700HT fast real-time PCR system from ABI. Compre-
hensive coverage of Sanger miRBase v14 was enabled via a
two-card set of TaqMan® Array MicroRNA Cards (Cards
A and B) for a total of 754 assays specific to 664 unique
human miRNAs. In addition, each card contains one
selected endogenous control assay (MammU6; printed
four times), five human endogenous controls (RNU 6B,
24, 43, 44, 48) that are the most highly abundant and sta-
bly expressed across all tissues, and one negative control
assay (ath-miR159a). Card A focused on more highly char-
acterized miRNAs, while Card B contained more recently
discovered miRNAs along with the miR* sequences.
RNA from paired tumor and normal esophageal tissues
were run together in parallel in the same experiment. The
protocol followed the manufacturer’s manual at http://
www3.appliedbiosystems.com/cms/groups/mcb_support/doc-
uments/generaldocuments/cms_042167.pdf. Briefly, three uL
of total RNA (350-1000ng) was added to 4.50uL of RT re-
action mix, which consisted of 10x Megaplex RT Primers,
100mM dNTPs with dTTP, 50U/uL MultiScribe Reverse
Transcriptase, 10x RT buffer, 25mM MgCl2, 20U/uL
RNase Inhibitor, and nuclease-free H2O. The samples
were run on a thermal cycler using the following condi-
tions: 40 cycles of 16 °C for two min, 42 °C for one min,
and 50 °C for one sec. All reactions were completed with
a final incubation of 85 °C for five min. Six uL of cDNA
generated from the thermal cycler was mixed with 450uL
of 2x TaqMan Universal PCR Master Mix with no
AmpErase UNG, and 444uL of nuclease-free H2O. 100uL
of the reaction mix was added to each of eight fill ports on
the TaqMan MicroRNA Array. The filled Array was
centrifuged twice at 1200 rpm for one min, and then
sealed with the eight fill ports removed. The array
was run on the 7900HT RT-PCR System with SDS
software. The comparative CT method was used to
determine the expression levels of mature miRNAs.
The GEO accession number for these miRNA data is
GSE66274.
GeneChip 500K array data analysis
Probe intensity data from Affymetrix 500K SNP arrays
were used to identify DNA alterations in the present
study. To avoid gender-related issues, SNPs mapped to
either the X or Y chromosome were excluded. Affymetrix
SNP array data were first normalized using the gtype-
probe set-genotype package included in Affymetrix Power
Tools version 1.85. Each tumor sample was individually
normalized via the BRLMM algorithm along with 99
blood samples. These blood samples were obtained from
the 30 ESCC cases evaluated in the present study plus 69
healthy controls (age-, sex-, and region-matched to the
cases) who were all part of a larger case–control study of
upper gastrointestinal (UGI) cancers conducted in Shanxi
Province [21]. Biallelic loss, including loss of both alleles
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in heterozygotes as well as homozygous deletions, was de-
termined based on comparison of matched tumor versus
germline DNA. Several criteria were used to determine
biallelic loss as follows: 1) a SNP with biallelic loss must
have (a) a “No Call” genotype call in the tumor sample; (b)
a high quality genotype call in the normal sample; and (c)
reduced copy number (CN0 or CN1); 2) analysis was
limited to SNPs in genes (exons and introns only); and 3)
analysis was limited to SNPs that fulfilled elements from
criterion #1 (a) to (c) in at least 10 % of the 30 ESCC cases
studied. Analyses of LOH and CN were described
previously [5, 6].
Human genome U133A 2.0 array data analysis and
relation between biallelic loss and mRNA expression
For all of the Affymetrix U133 array data, raw data sets
(CEL files on all samples) after scanning were normalized
using RMA as implemented in Bioconductor in R (http://
www.bioconductor.org), including background correction
and normalization across all samples. For each sample,
log2 fold changes in gene expression were calculated by
subtracting the adjacent normal RMA value from the
corresponding tumor RMA value.
To assess the influence of biallelic loss on expression,
we performed the following steps: (i) First, genes assayed
by the U133A microarray were mapped onto each biallelic
loss segment of each sample. Map locations of genes were
taken from the Affymetrix version na29 microarray
annotation file. (ii) We then performed two-sided un-
paired Wilcoxon rank sum tests comparing the log2 fold
changes for a probe set in biallelic loss positive and
negative samples. A P-value <0.05 was considered sig-
nificant. (iii) Finally, SNPs on the 500K microarray were
mapped to the reference sequence for each expression
probe set. Average fold changes were used to relate
mRNA expression to DNA biallelic loss.
ABI miRNA expression array analysis
RQ Manager integrated in software from ABI was used
to normalize the entire signal generated. Expression level
(as fold change) was calculated when both tumor and
normal samples had signals in the assays using DataAssist
software v2.0 (Life Technologies, http://www.lifetechnolo-
gies.com/about-life-technologies.html). Signals for miRNA
that showed either in tumor only or normal only were
dropped from analysis. Fold change was calculated using
the 2 -ΔΔCT method. In the present study, the data are pre-
sented as fold change in the target gene expression in tu-
mors normalized to the internal control gene (MammU6)
and relative to the normal tissue control (matched normal
as calibrator). Results of the real-time PCR data are repre-
sented as CT values, with CT defined as the threshold cycle
number of PCRs at which amplified product was first de-
tected. The average CT was calculated for both the target
gene and MammU6 and the ΔCT was determined as (the
mean of up to three CT values for the target gene) minus
(the mean of the CT values for U6). The ΔΔCT repre-
sented the difference between the paired tissue sam-
ples, as calculated by the formula ΔΔCT = (ΔCT of
tumor - ΔCT of normal). The N-fold differential
expression in the target gene of a tumor sample com-
pared to its normal sample counterpart was expressed
as 2 -ΔΔCT. For each case, the frequency of dysregulated
miRNAs was calculated as the number of dysregulated
miRNAs divided by the total number of miRNAs that
showed signals in both tumor and normal. The criteria
used to call an miRNA dysregulated were fold changes ≥ 2
or ≤ 0.5.
We used TargetScan (http://www.targetscan.org/) (White-
head Institute for Biomedical Research, Cambridge, MA,
USA) and Sanger miRBase (http://www.mirbase.org/) to
identify conserved miRNAs in the 3′ UTR for affected
genes, which are thought to be preferentially conserved.
We used median fold change for both miRNA and
mRNA in our analysis of the relation between expressions
of miRNA and genes. Correlations and p-values between
selected variables were performed using Spearman rank
correlations and Wilcoxon rank tests.
Results
A flow diagram detailing the various laboratory analyses
performed in the study can be found in Additional file 1:
Figure S1.
Genes with frequent biallelic loss
The overall average genotype call rate was 95 % in the
present study for the 60 chips evaluated: average call rates
for the 250K Nsp chip were 95 % for both germline DNA
(range 93–98 %) and tumor DNA (range 91–97 %), and
average call rates for the 250K Sty chip were 96 % (range
90–98 %) for germline DNA and 95 % (range 92–97 %)
for tumor DNA.
We identified 702 SNPs that showed frequent biallelic
loss, that is, in at least 10 % (at least three cases) of
ESCC tumors (see “Methods” section). Those 702 SNPs
mapped to 77 genes and represent 9.4 % of the total of
7484 SNPs in those genes on our SNP array. Nearly all
of the 77 genes represented by these SNPs were concen-
trated on just four chromosomal arms (ie, 42 genes on
3p, 14 on 9p, 10 on 5q, and 7 on 4p). Table 1 summa-
rizes biallelic loss frequencies for each of the 77 genes,
including the number of cases with biallelic loss, the
number of SNPs with biallelic loss in at least three cases,
the number of SNPs mapped within the gene and
present on the SNP array, and the fraction of the SNPs
with biallelic loss among all the SNPs in the gene. Some
of the genes shown in Table 1 are known cancer-
associated genes (ie, FOXP1, CSMD1, CDKN2A/2B,
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Cytoband No. cases with biallelic
loss




Fraction of SNPs in gene with biallelic
loss
on 2q
1 SPAG16 2q34 8 7 164 0.04
on 3p
2 CADM2 3p12.1 9 6 44 0.14
3 CNTN3 3p12.3 11 9 56 0.16
4 ROBO1 3p12.3 9 6 60 0.10
5 ROBO2 3p12.3 11 18 93 0.19
6 EIF4E3 3p13 9 6 16 0.38
7 ADAMTS9 3p14.1 10 10 52 0.19
8 FAM19A1 3p14.1 11 15 128 0.12
9 FOXP1 3p14.1 12 10 104 0.10
10 MAGI1 3p14.1 10 12 192 0.06
11 PRICKLE2 3p14.1 9 7 56 0.13
12 SUCLG2 3p14.1 10 13 66 0.20
13 CADPS 3p14.2 10 11 137 0.08
14 FHIT 3p14.2 12 31 345 0.09
15 PTPRG 3p14.2 10 28 199 0.14
16 CACNA2D3 3p14.2-
p21.1
11 22 246 0.09
17 ERC2 3p14.3 9 8 211 0.04
18 PBRM1 3p21.1 7 8 19 0.42
19 CACNA2D2 3p21.31 10 9 17 0.53
20 DOCK3 3p21.31 7 8 57 0.14
21 MYRIP 3p22.1 9 8 66 0.12
22 TRAK1 3p22.1 9 9 39 0.23
23 DLEC1 3p22.2 10 5 12 0.42
24 ITGA9 3p22.2 11 14 101 0.14
25 SLC22A14 3p22.2 8 7 11 0.64
26 GPD1L 3p22.3 9 5 14 0.36
27 OSBPL10 3p23 9 6 63 0.10
28 LRRC3B 3p24.1 7 5 12 0.42
29 RBMS3 3p24.1 12 10 166 0.06
30 RARB 3p24.2 8 5 42 0.12
31 THRB 3p24.2 9 9 84 0.11
32 RFTN1 3p24.3 11 13 54 0.24
33 UBE2E2 3p24.3 10 9 55 0.16
34 ZNF385D 3p24.3 12 21 108 0.19
35 SLC6A6 3p25.1 8 5 14 0.36
36 ATP2B2 3p25.3 9 10 108 0.09
37 SRGAP3 3p25.3 9 12 97 0.12
38 GRM7 3p26.1 11 38 276 0.14
39 LMCD1 3p26.1 9 5 36 0.14
40 ITPR1 3p26.2 11 16 121 0.13
41 CHL1 3p26.3 7 6 78 0.08
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Table 1 Description of genes with frequent biallelic loss in ESCC1 (Continued)
42 CNTN4 3p26.3 10 11 163 0.07
43 CNTN6 3p26.3 8 6 111 0.05
on 4p & 4q
44 PCDH7 4p15.1 11 6 58 0.10
45 KCNIP4 4p15.31 10 22 338 0.07
46 LDB2 4p15.32 7 5 103 0.05
47 EVC 4p16.1 8 5 41 0.12
48 EVC2 4p16.1 6 5 45 0.12
49 SORCS2 4p16.1 6 5 115 0.04
50 WDR1 4p16.1 7 5 12 0.42
51 FSTL5 4q32.2 11 10 126 0.08
52 GALNT17 4q34.1 7 6 187 0.03
on 5q
53 RGS7BP 5q12.3 8 5 37 0.14
54 IQGAP2 5q13.3 8 8 87 0.09
55 SV2C 5q13.3 7 5 67 0.07
56 GPR98 5q14.3 5 6 95 0.06
57 MCTP1 5q15 6 5 98 0.05
58 PPP2R2B 5q32 7 8 114 0.07
59 CYFIP2 5q33.3 7 6 41 0.15
60 DOCK2 5q35.1 6 6 166 0.04
61 SLIT3 5q35.1 7 5 221 0.02
62 COL23A1 5q35.3 9 8 68 0.12
on 8p
63 CSMD1 8p23.2 7 4 153 0.03
on 9p
64 LNGCO2 9p21.1 9 6 140 0.04
65 CDKN2A/
2B
9p21.1 8 3 6 0.50
66 KIAA1797 9p21.3 5 5 57 0.09
67 MTAP 9p21.3 8 4 17 0.24
68 ADAMTSL1 9p22.1 9 7 108 0.06
69 C9orf138 9p22.1 7 5 37 0.14
70 BNC2 9p22.2-
p22.3
8 7 99 0.07
71 JMJD2C 9p24.1 9 6 151 0.04
72 PTPRD 9p24.1 9 17 199 0.09
73 UHRF2 9P24.1 5 6 19 0.32
74 GLIS3 9p24.2 7 5 155 0.03
75 ANKRD15 9P24.3 6 7 103 0.07
76 DOCK8 9p24.3 7 5 65 0.08
77 SMARCA2 9p24.3 6 5 63 0.08
1Genes listed in order by chromosome location
2No. SNPs with biallelic loss in 3 or more cases
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FHIT, DLEC1, and RARB). Genes affected by biallelic
loss were relatively rare (77 genes with biallelic loss
divided by an estimated 22,775 genes represented on
the Affymetrix array equals approximately 0.0034 or
0.34 %), and far less common than LOH or copy
number alterations in ESCC. However, such alterations
could be more severe and consequently might have
greater impact on tumorigenesis.
We also examined our ESCC cases by the frequency
of biallelic loss frequency among the 7484 SNPs in
the 77 genes with biallelic loss (Table 2). Fourteen
cases had at least 100 SNPs with biallelic loss and
were termed “higher biallelic loss cases”, whereas the
remaining 16 cases had fewer than 100 SNPs with
biallelic loss and were called “lower biallelic loss
cases.” Table 2 summarizes DNA changes (biallelic
loss, LOH, and DNA copy number alterations) among
the 7848 SNPs in the 77 genes with biallelic loss for
each of the 30 ESCC cases. The number of SNPs
affected by LOH and copy number alterations varied
widely among cases. The number of SNPs with biallelic
loss was highly correlated with both the number of SNPs
with LOH (r = 0.92, p = 4.41E-13) and the number of
SNPs with copy number loss (r = 0.97, p = 3.94E-19), but
was not significantly correlated with either the number of
SNPs with copy number gain (r = 0.21, p = 0.26) or the
Table 2 Description of DNA alterations in SNPs found in genes with frequent biallelic loss among ESCC cases1
Row no. Case no. No. SNPs with biallelic loss No. SNPs with LOH No. SNPs with CN loss No. SNPs with CN gain No. SNPs with CN neutral LOH
1 E24 1304 479 5173 0 9
2 E4 1251 193 3686 0 166
3 E30 1082 799 4449 0 15
4 E27 895 436 3858 0 114
5 E14 796 338 3845 0 266
6 E26 769 928 4115 0 310
7 E6 762 114 2244 107 173
8 E23 720 583 3870 0 21
9 E29 707 185 3384 191 164
10 E22 657 661 2722 133 217
11 E17 435 272 2735 428 340
12 E10 283 60 1474 746 41
13 E13 213 71 1411 824 202
14 E8 170 44 1341 118 0
15 E18 91 8 1089 282 137
16 E1 90 69 383 0 956
17 E11 70 126 343 0 1193
18 E28 53 9 1063 0 31
19 E25 47 4 370 111 426
20 E9 29 1 538 67 29
21 E16 29 0 164 0 64
22 E2 21 0 245 0 81
23 E7 17 1 108 0 95
24 E21 6 1 16 0 673
25 E3 1 0 26 0 72
26 E5 0 0 0 0 45
27 E12 0 0 18 0 13
28 E15 0 0 4 0 14
29 E19 0 0 11 0 23
30 E20 0 0 0 0 53
1Cases listed in order by no. SNPs with biallelic loss; cases with 100+ SNPs with biallelic loss = ‘higher loss cases’, <100 = ‘lower loss cases’
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number of SNPs with copy number neutral LOH (r = 0.18,
p = 0.34).
We also checked for microdeletions or biallelic loss
regions on chromosomes (eg, 3p14) caused by continuous
SNPs with biallelic loss, but were unable to identify any.
Biallelic loss and expression of mRNA and miRNA
Among the 77 genes with biallelic loss, 52 had probes rep-
resented on the Affymetrix Hu 133 array with signals in
both tumor and normal tissues. We found that 41 of these
52 genes (79 %) had lower mRNA expression levels in
cases with biallelic loss than cases with no biallelic loss
(the 41 genes shown in the unshaded area on the left in
Fig. 1), including eight genes in which mRNA expression
was statistically significantly lower (Additional file 2: Table
S1). For example, the mean fold change in MTAP expres-
sion was 0.83 in cases with biallelic loss versus 1.11 in
cases with no biallelic loss (P = 0.009). Eleven genes had
expression levels that were the same or higher in cases
with biallelic loss than cases with no loss (the 11 genes in
the shaded area on the right in Fig. 1). As an example, the
median fold change for expression of ADAMTS9 was 1.35
in cases with biallelic loss compared to 1.0 in cases with-
out biallelic loss (Additional file 2: Table S1). Although ex-
pression differences observed were modest, these results
suggest that biallelic loss appeared to influence gene
expression.
Expression of miRNAs by biallelic loss status is shown
in Additional file 3: Table S2. The ratio of miRNA expres-
sion in target genes with biallelic loss (versus without) was
greater than one for 34 of 60 (57 %) miRNAs and less than
one in 26 of 60 (43 %).
miRNA expression and target gene expression in genes
with frequent biallelic loss
There were a total of 664 miRNAs on the ABI Chips A &
B in our analysis. Two hundred sixty-eight miRNAs were
excluded from further analysis because of inadequate data
(ie, signal was present only in tumor or only in normal, or
signal was absent altogether because of tissue specificity),
leaving 396 miRNAs that showed signals in both the
tumor and the normal tissues in at least 10 % of the 30
ESCC cases (ie, at least three cases) for our analyses
(Additional file 4: Table S3 and Additional file 5: Table S4).
We checked the conserved miRNA targets in the 3′
UTRs for the 52 genes with mRNA results using http://
www.targetscan.org/ and found 44 genes that could be
targeted by one or more of the miRNAs present on the
ABI miRNA array. After further filtering (ie, seven
genes were not targeted by miRNAs on our array, and
two genes had miRNA signals in less than three cases),
we had data available to analyze the relation between
the expression of 70 miRNAs (58 targeted just one gene
and 12 targeted multiple genes) and 35 gene targets in
our 30 ESCC cases (Additional file 6: Table S5). We
found a relatively wide range of miRNA expression levels
among these gene targets (tumor:normal miRNA fold
change median = 1.62, range 0.08 to 5.27; Additional file 7:
Table S6). Overall, in the 35 genes with biallelic loss that
were evaluable, miRNA expression levels were more often
elevated (fold change > 1.0) than mRNA expression levels
(69 % versus 14 %, respectively). When miRNA and
mRNA were examined together, expression levels of 41
(of 70) miRNAs were elevated (fold change > 1.0) while
their target gene expression levels were reduced (fold
change < 1.0). Examples of interesting miRNA-target gene
Fig. 1 mRNA expression by biallelic loss status for 52 genes in ESCC. X-axis: names of 52 genes present on the Affymetrix HU 133 A chip with a
signal present in both tumor and matched normal tissues; Y-axis: gene expression fold changes (median log 2 ratio) in cases with biallelic loss
(red) and in cases without biallelic loss (green)
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pairs that showed this pattern were: expression of miR-
205 was 3.11-fold and its target gene ADAMTS9 expres-
sion was 0.87-fold; miR-124 was 3.79-fold and its target
gene SUCLG2 was 0.42-fold; and expression of miR-183
was 3.01-fold while its target FOXP1 was 0.76-fold. Con-
versely, 17 miRNAs showed reduced expression in
both the miRNA and its target gene. An illustrative
example of this relation is the 0.17-fold expression
change for miR-133b0.85-fold in its target gene
IQGAP expression. Taken together, our results indi-
cate that miRNA expression levels varied widely.
Increased miRNA most often was associated with re-
duced target gene expression, but reduced target gene
expression was also frequently seen with reduced
miRNA in ESCC.
Discussion
In the present study, we took an integrative approach by
evaluating genes in relation to biallelic loss and expres-
sion of both mRNA and miRNA in ESCC cases using
profiling data generated from arrays. We made several
observations from our evaluation of these data. First,
biallelic loss was relatively uncommon, but when it
occurred it was concentrated in four chromosome arms,
namely, 3p, 9p, 5q, and 4p. Second, biallelic loss ap-
peared to affect gene expression; nearly 80 % of genes in
cases with biallelic loss showed reduced mRNA expres-
sion compared to those without loss. Third, although the
relation was less clear than for mRNA, biallelic loss also
appeared to affect miRNA expression. More informative
future studies will need larger sample sizes so as to have
more heterozygous SNPs for evaluation, and appropriate
coverage of promoter regions, to confirm and expand our
findings here regarding relations between SNPs with
biallelic loss and expression of mRNA and miRNA.
Distributions of miRNA expressions were generally
higher in cases with biallelic loss than in cases without
loss. Of 60 miRNA-target gene pairs, 34 pairs (57 %) had
higher miRNA expression with biallelic loss than without,
while 26 pairs (43 %) had lower miRNA expression.
Finally, the effect of biallelic loss on the relation between
miRNA and mRNA expression was complex. Biallelic loss
was most commonly associated with a pattern of elevated
miRNA and reduced mRNA (43 %), but a pattern of both
reduced miRNA and mRNA was also common (35 %).
In our study, 77 genes showed biallelic loss and half of
these genes were located on chromosome 3p, our most
common site of loss. The frequency of biallelic loss
among the 42 genes on chromosome 3p ranged from 5 %
to 64 % (Table 1). This region includes several tumor
suppressor genes (eg, ROBO1, FOXP1, FHIT). Our
previous studies also showed high frequency of LOH
on chromosome 3p in ESCC [5]. Taken together, bial-
lelic loss, similar to LOH, appears to play a role in
the stability of chromosome 3p in ESCC. Although
most SNPs that show biallelic loss and/or LOH are lo-
cated in the non-coding regions of these genes, they may
exert their effects via gene expression. For example, bial-
lelic loss of CHL1 (3p26.3) affected six of 78 SNPs, and
the expression level of CHL1 was reduced in cases with
biallelic loss but elevated in cases without biallelic loss
(Additional file 2: Table S1), while miRNA-10a and
miRNA-10b expression levels, which both target CHL1,
were higher in cases with biallelic loss than those with-
out (Additional file 3: Table S2). Interestingly, a previous
study showed that miR-10b may play a causal role in indu-
cing metastatic behavior [22]. We note that expression
levels for some genes did not show big differences by
biallelic loss status, or even higher expression levels
in cases with biallelic loss than those without. One
potential explanation for this finding is epigenetic al-
terations such as DNA methylation changes.
Our results indicate that ESCC tumors may be divided
into two groups: those with high and those with low
levels of genome instability as assessed by the number of
SNPs with biallelic loss (Table 2), suggesting that the
genetic stability is variable, even among patients from a
seemingly homogeneous population with extraordinarily
high rates of esophageal cancer. Our results also show
that both miRNA and mRNA levels varied widely despite
the fact that the esophageal cancer patients studied here
were similar in many important ways (eg, from the same
geography, had the same tumor histology, and had similar
clinical characteristics such as stage) [5], suggesting that
ESCC is incredibly complex and that there is significant
heterogeneity among ESCC patients. This is likely one
reason why tumors that appear similar can progress and
respond to therapy in dramatically different ways. New
insights gained from better understanding of case/
tumor heterogeneity should be useful for predicting
response to therapy [23, 24].
Although several studies have evaluated biallelic loss/
homozygous deletion within specific genes in tumors
(e.g., CDKN2A [25]), including ESCC [26], using tech-
niques such as FISH, only a few prior reports have used
genome-wide techniques such as SNP or comparative
genomic hybridization (CGH) arrays to agnostically as-
sess homozygous deletions in tumor cell lines or tissues.
Cancers evaluated for biallelic loss with array technol-
ogy include prostate (SNP array) [25, 27], B-cell lymph-
omas (CGH array) [28], and B-cell chronic lymphocytic
leukemia (SNP array) [29]. Among the largest of these
studies, Guichard et al. used CGH arrays and recently
reported that 40 % of 125 hepatocellular carcinomas
had homozygous deletions [30]. Twelve regions were re-
currently altered, including most frequently loci at
CDKN2A-CDKN2B (6.4 %), AXIN1 (3.2 %), and IRF2
(3.2 %). To the best of our best knowledge, our study
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is the first report of biallelic loss identified in genes in
ESCC cases using array technology.
We note that there are several limitations in the current
study, most notably our small sample size. In addition,
most of the SNPs identified with biallelic loss were in
introns of genes, and our small sample size precluded
detailed assessment of interactions among DNA, RNA,
and miRNA. A major strength of this study is that all 30
ESCC cases reported were evaluated using the same array
platforms and every case had both tumor and normal
tissue DNA, RNA, and miRNA profiled using genome-
wide methods, so that our comparisons are comprehen-
sive and carefully controlled paired comparisons within
the same case.
Conclusion
In conclusion, our results indicate that biallelic loss in
ESCC is uncommon, but when it occurs it is localized to
a few specific chromosomal regions and appears to influ-
ence mRNA expression of affected genes, leading to
complex patterns of expression of miRNA and target
genes in ESCC patients.
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